Share article:
Share article:

US buys up global stock of promising Covid-19 drug

Credit: Belga

The US government has bought up virtually all the global stock of remdesivir, one of the most promising drugs to treat Covid-19 patients, leaving nothing for Europe.

An agreement with biotech company Gilead Sciences provides for the purchase of drug doses for more than 500,000 treatments, according to the US Department of Health.

This corresponds to 100% of the planned production volume for July, and 90% for August and September.

Several studies have shown that the drug can shorten patients’ hospital stay.

“[The US] has got access to most of the drug supply, so there is nothing for Europe,” pharmaceutical expert Andrew Hill of the University of Liverpool in the United Kingdom told The Guardian.

Gilead said to have agreed with the US government that unallocated parts of production “could be made available for other uses, including outside the United States.” Hospital needs will be closely monitored and evaluated every two weeks, reports Het Nieuwsblad.

Related News:

 

The cost is around $3,200 (approximately €2,843) per treatment course, according to the US government statement.

Last week, the European Medicines Agency (EMA) recommend that the drug Veklury (remdesivir) be given a conditional marketing authorisation for the treatment of Covid-19 patients. A decision of the European Commission is expected later this week.

Remdesivir was originally developed for the treatment of Ebola, but was not effective enough. So far, it has not been approved as a drug in any country in the world.

As of Wednesday, the US has recorded more than 2.7 million confirmed cases of Covid-19, and over 130,000 deaths since the start of the pandemic.

Maïthé Chini
The Brussels Times

Latest news

Warnings issued for slippery roads across Belgium
Drivers have been asked to watch out for slippery roads from Saturday afternoon until Sunday evening, as snow and cold temperatures are expected ...
Testing rules following high-risk contact eased for vaccinated people
The coronavirus testing policy following a high-risk contact has been eased, meaning a vaccinated person who was in contact with an infected person ...
New measures announced for Belgian schools
Stricter rules are being implemented across a variety of sectors in Belgium to curb the rising number of infections and limit the damage as a result ...
Majority of booster doses should be administered by March 2022
Invitations will be sent out in the following days for the general population in Belgium to receive a coronavirus booster vaccine, and most adults ...
Belgium adopts national plan to combat gender-based violence
Belgium has adopted a National Action plan for the Fight against Gender-Based Violence, which includes more than 200 measures and unites all levels ...
Antwerp cancels Christmas market and New Year’s Eve fireworks
The city of Antwerp has joined other cities including Leuven and Ghent by announcing it is cancelling this year's Christmas market, the end-of-year ...
Pharmaceutical companies looking into vaccines against new variant
Pharmaceutical companies have sprung into action to look into vaccine protection against the new coronavirus variant first detected in South Africa, ...
Belgium imposes entry ban on travellers from southern Africa
Belgium is introducing an entry ban for travellers from several countries in the south of Africa following concerns about a new variant (B.1.1.529) ...
What Ursula did next
BRUSSELS BEHIND THE SCENES • Weekly analysis and untold stories
Nightclub closures, limiting contacts: These rules come into force today
Just over one week after its last meeting, Belgium's Consultative Committee on Friday once again announced a set of new measures to curb the rising ...
Almost 3,500 Covid-19 patients in hospitals as new cases continue to skyrocket
The number of new coronavirus cases in Belgium is continuing to rise, and with it the number of Covid-19 patients who are hospitalised as a result of ...
ECDC issues threat assessment about new COVID-19 variant, WHO designates it as a variant of concern
Preliminary data on the risks of the new COVID variant of concern is high, the European Centre for Disease Prevention and Control (ECDC) said late ...